Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Henriette Balinda
Observed name:
Henriette U Balinda
Institution:
The University of Texas at San Antonio Health Science Center
Observed institutions:
The University of Texas at San Antonio Health Science Center,
Mays Cancer Center at UT Health San Antonio
ORCID:
0000-0001-6878-8656
Observed ORCID:
0000-0001-6878-8656
OpenAlex ID:
A5076628343
ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics
2022
·
Adam Kosti
, Jennifer Chiou
, et al.
·
Neuro-Oncology
·
23
PDF
A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma.
2024
·
William Kelly
, Christine Cordova
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer.
2023
·
Avani Gunuganti
, Henriette Balinda
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Ctni-36. Sacituzumab Govitecan for Recurrent Glioblastoma
2023
·
William Kelly
, Henriette Balinda
, et al.
·
Neuro-Oncology
·
1
PDF
Ctni-10. Sacituzumab Govitecan for Breast Cancer Brain Metastasis
2023
·
Henriette Balinda
, William Kelly
, et al.
·
Neuro-Oncology
·
1
PDF
Abstract P1-14-04: A Phase 0 Clinical trial of Sacituzumab Govitecan in Patients with Breast Cancer Brain Metastases and Recurrent Glioblastoma
2023
·
Pegah Ghamasaee
, Henriette Balinda
, et al.
·
Cancer Research
·
1
LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases
2021
·
Maria Guerra-Garcia
, Henriette Balinda
, et al.
·
Neuro-Oncology Advances
·
1
Cltr-06 Respect-lm: Pharmacokinetic and Pharmacodynamic Assessment of Rhenium Obisbemeda in Leptomeningeal Metastases With Emerging Data From Repeated Dosing (respect-lmm)
2026
·
Andrew Brenner
, Henriette Balinda
, et al.
·
Neuro-Oncology Advances
Africa’s Regulatory Revolution: How Harmonized Regulation Can Transform Global Clinical Trials
2026
·
Henriette Balinda
, Alima Tchafa
, et al.
·
Open Access Journal of Clinical Trials
Abstract P3-04-28: Inhibition of FASN and ACC1 as a Potential Treatment for Advanced Endocrine Therapy-Resistant Breast Cancer
2025
·
Henriette Balinda
, Avani Gunuganti
, et al.
·
Clinical Cancer Research
Ctni-26. a Phase Ii Study of Sacituzumab Govitecan in Recurrent Glioblastoma
2024
·
William Kelly
, Christine Cordova
, et al.
·
Neuro-Oncology
PDF
Abstract 4422: Metabolic adaptations of glioblastoma in hypoxia is mediated by acox-1
2024
·
Ayon Bhattacharya
, Laura Caflisch
, et al.
·
Cancer Research
Abstract P3-11-07: Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer
2023
·
Henriette Balinda
·
Cancer Research
Cnsc-18. Hypoxia-induced Metabolic Adaptations Through Acox-1 in Glioblastoma
2022
·
Ayon Bhattacharya
, Laura Caflisch
, et al.
·
Neuro-Oncology
PDF
Abstract P5-05-10: Inhibition of FASN as a potential treatment of advanced therapy-resistant breast cancer
2022
·
Henriette U Balinda
·
Cancer Research
Show more works
View as search
Works count:
15
Citation count:
33
H-index:
3
I10-index:
1
Year
Topic
Type